secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000950170-23-063021
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma Q3 2023: Revenue $16.9M, cash runway into H1 2025; luvelta data and new CSO
--------------------------------------------------------------------------------

- Cash and investments $321.1M plus Vaxcyte shares valued at $34.0M projecting runway into first half 2025.
- Q3 2023 revenue $16.9M, down from $25.1M in Q3 2022; operating expenses $60.9M vs $46.4M.
- Luvelta showed encouraging anti-tumor activity in FolRα-selected endometrial cancer at ESMO 2023; AML compassionate use data at ASH 2023.
- Dr. Hans-Peter Gerber appointed Chief Scientific Officer in September 2023.
- REFRaME-O1 Phase 2/3 trial for platinum-resistant ovarian cancer enrollment underway; global registration discussions with FDA/EMA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023063021/0000950170-23-063021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023063021/stro-20231113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer